<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">75529</article-id><article-id pub-id-type="doi">10.7554/eLife.75529</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Role of oxidation of excitation-contraction coupling machinery in age-dependent loss of muscle function in <italic>C. elegans</italic></article-title></title-group><contrib-group><contrib contrib-type="author" id="author-260619"><name><surname>Dridi</surname><given-names>Haikel</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9533-7367</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-263096"><name><surname>Forrester</surname><given-names>Frances</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-268365"><name><surname>Umanskaya</surname><given-names>Alisa</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-268366"><name><surname>Xie</surname><given-names>Wenjun</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-263099"><name><surname>Reiken</surname><given-names>Steven</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-70204"><name><surname>Lacampagne</surname><given-names>Alain</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-254899"><name><surname>Marks</surname><given-names>Andrew</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8057-1502</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="other" rid="par-7"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><institution content-type="dept">Department of Physiology and Cellular Biophysics</institution>, <institution>Columbia University Medical Center</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">U1046</institution>, <institution>Montpellier University, INSERM, CNRS</institution>, <addr-line><named-content content-type="city">Montpellier</named-content></addr-line>, <country>France</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-113901"><name><surname>Nelson</surname><given-names>Mark T</given-names></name><role>Reviewing editor</role><aff><institution>University of Vermont</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>arm42@cumc.columbia.edu</email> (AM);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>04</day><month>05</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e75529</elocation-id><history><date date-type="received"><day>12</day><month>11</month><year>2021</year></date><date date-type="accepted"><day>27</day><month>04</month><year>2022</year></date></history><permissions><copyright-statement>Â© 2022, Dridi et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Dridi et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-75529-v1.pdf"/><abstract><p>Age-dependent loss of body wall muscle function and impaired locomotion occur within 2 weeks in <italic>C. elegans</italic>; however, the underlying mechanism has not been fully elucidated. In humans, age-dependent loss of muscle function occurs at about 80 years of age and has been linked to dysfunction of ryanodine receptor (RyR)/intracellular calcium (Ca<sup>2+</sup>) release channels on the sarcoplasmic reticulum (SR). Mammalian skeletal muscle RyR1 channels undergo age-related remodeling due to oxidative overload, leading to loss of the stabilizing subunit calstabin1 (FKBP12) from the channel macromolecular complex. This destabilizes the closed state of the channel resulting in intracellular Ca<sup>2+</sup> leak, reduced muscle function, and impaired exercise capacity. We now show that the <italic>C. elegans</italic> RyR homolog, <italic>UNC-68</italic>, exhibits a remarkable degree of evolutionary conservation with mammalian RyR channels and similar age-dependent dysfunction. Like RyR1 in mammals <italic>UNC-</italic>68 encodes a protein that comprises a macromolecular complex which includes the calstabin1 homolog FKB-2 and is immunoreactive with antibodies raised against the RyR1 complex. Further, as in aged mammals, <italic>UNC-68</italic> is oxidized and depleted of FKB-2 in an age-dependent manner, resulting in 'leaky' channels, depleted SR Ca<sup>2+</sup> stores, reduced body wall muscle Ca<sup>2+</sup> transients, and age-dependent muscle weakness. FKB-2 <italic>(ok3007)-</italic>deficient worms exhibit reduced exercise capacity. Pharmacologically induced oxidization of <italic>UNC-68</italic> and depletion of FKB-2 from the channel independently caused reduced body wall muscle Ca<sup>2+</sup> transients. Preventing FKB-2 depletion from the <italic>UNC-68</italic> macromolecular complex using the Rycal drug S107 improved muscle Ca<sup>2+</sup> transients and function. Taken together, these data suggest that <italic>UNC-68</italic> oxidation plays a role in age-dependent loss of muscle function. Remarkably, this age-dependent loss of muscle function induced by oxidative overload, which takes ~2 years in mice and ~80 years in humans, occurs in less than 2-3 weeks in <italic>C. elegans</italic>, suggesting that reduced antioxidant capacity may contribute to the differences in life span amongst species.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>C. elegans</italic></kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>R01HL145473</award-id><principal-award-recipient><name><surname>Marks</surname><given-names>Andrew</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>R01DK118240</award-id><principal-award-recipient><name><surname>Marks</surname><given-names>Andrew</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>R01HL142903</award-id><principal-award-recipient><name><surname>Marks</surname><given-names>Andrew</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>R01HL061503</award-id><principal-award-recipient><name><surname>Marks</surname><given-names>Andrew</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>R01HL140934</award-id><principal-award-recipient><name><surname>Marks</surname><given-names>Andrew</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000069</institution-id><institution>National Institute of Arthritis and Musculoskeletal and Skin Diseases</institution></institution-wrap></funding-source><award-id>R01AR070194</award-id><principal-award-recipient><name><surname>Marks</surname><given-names>Andrew</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>T32HL120826</award-id><principal-award-recipient><name><surname>Marks</surname><given-names>Andrew</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Andrew Marks, owns stock in ARMGO, Inc. a company developing compounds targeting RyR and has patents on Rycals.US 2014/0378437, and US 7,718,644..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data are described/available in the manuscript</p></sec><supplementary-material><ext-link xlink:href="elife-75529-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>